INTRODUCTION
============

Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective anti-inflammatory, antipyretic, and analgesic agents and are among the most widely prescribed drugs worldwide \[[@R1]\]. However, despite their accepted efficacy, it is well recognized that use of NSAIDs is associated with an increased risk of gastrointestinal (GI) damage, including overt bleeding, ulceration, occult blood loss, and the development of clinically significant anemia or blood loss \[[@R2],[@R3]\].

Recent evidence suggests some patients with mildly low or low-normal hemoglobin levels may have an increased risk of frailty, poor functional outcomes, hospitalization, and mortality \[[@R4]-[@R7]\]. In the recent Celecoxib versus Omeprazole and Diclofenac in Patients with Osteoarthritis and Rheumatoid Arthritis (CONDOR) randomized clinical trial \[[@R8]\] comparing the risk of GI events through the entire GI tract, clinically significant anemia or blood loss (predefined as a *decrease in hemoglobin ≥2 g/dL and/or hematocrit ≥10% points from baseline*) was an important component of the composite primary GI endpoint \[[@R8]\]. Although blood loss is common in patients taking NSAIDs, few studies have been performed to determine the exact burden and clinical impact of this problem in patients taking NSAIDs or aspirin, or to determine whether blood loss is associated with other more clinically apparent adverse events (AEs). The objective of this analysis of pooled data from the celecoxib clinical trial database, including both patients treated with NSAIDs and placebo, was to investigate whether there is a clinically important difference in the AE profile of patients with clinically significant anemia or blood loss (predefined as a *decrease in hemoglobin ≥2 g/dL and/or hematocrit ≥10% points from baseline*) compared with patients without such blood loss, regardless of treatment.

MATERIALS AND METHODOLOGY
=========================

Study Design and Selection
--------------------------

This was a retrospective, pooled analysis of 51 blinded, controlled clinical studies comparing celecoxib, a cyclooxygenase (COX)-2 selective NSAID, with other COX-2 selective and nonselective NSAIDs (nsNSAIDs) or placebo. To be eligible for inclusion, all clinical study reports (from Pfizer's Celecoxib Clinical Trial Database) must have been finalized by October 1, 2007; only randomized, double-blind controlled clinical trials with at least one celecoxib and one comparator (active or placebo) group, of a planned duration of daily treatment ≥4 weeks, were included. All open-label extensions, crossover trials, and healthy volunteer studies were excluded. With these criteria applied, the resulting pooled dataset represents both male and female patients with osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis (AS), chronic low back pain, Alzheimer disease, and/or spontaneous adenomatous colorectal polyps.

Data Collection
---------------

The primary end point was blood loss status (Y/N) defined as "Yes" if a patient had a *≥2 g/dL hemoglobin drop and/or ≥10% hematocrit drop from baseline.* This definition is consistent with the definition of clinically significant anemia or blood loss used (as a component of the composite primary GI end point) in both the CONDOR and Gastrointestinal Randomized Event and Safety Open-label NSAID Study (GI-REASONS) randomized clinical trials \[[@R8],[@R9]\]; the GI-REASONS study uses a prospectively randomized open-label blinded end point (PROBE) design (neither the CONDOR or GI-REASONS trials were included in this analysis, as they did not meet the clinical study report finalization date criterion).

To determine whether there were any clinically important consequences in patients with blood loss as defined above, the AE profile in patients with the blood loss status "Yes" was compared with the AE profile in patients without such blood loss. For the primary analysis, an AE was considered to be associated with blood loss if it occurred at any time during the time window from the last laboratory day normal hemoglobin/hematocrit values were recorded (before the first hemoglobin/hematocrit decrease), to the day hemoglobin/hematocrit values returned to normal ***or***30 days after the hemoglobin/hematocrit decrease, whichever occurred first (Fig. **[1](#F1){ref-type="fig"}**).

Statistical Analysis
--------------------

The pooled analysis was performed on the safety population (all patients who were randomized in any of the included 51 clinical trials who took at least one dose of study medication and who had at least one safety assessment). Summary statistics were used to compare AE profiles (preferred AE terms based on Medical Dictionary for Regulatory Activities, MedDRA 11.0) in patients who had clinically significant blood loss ("Yes" for the primary end point) versus patients who did not ("No" for the primary end point). When comparing the percentage of patients with specific AEs between the groups, a threefold difference was defined arbitrarily as being "markedly higher"; any AE that occurred for \<0.5% of patients in both groups was excluded from treatment comparisons.

RESULTS
=======

Included Studies
----------------

A total of 51 double-blind, randomized clinical trials met the criteria for inclusion and were pooled for this retrospective analysis (please see list of clinical trials, including details on study duration and comparator treatments in Table **[1](#T1){ref-type="table"}**). Study duration ranged from 4 weeks to 3 years. One study was event-driven, and thus patients in this study were exposed to study medication for different durations (median duration of 6-9 months), rather than for a protocol-defined time period.

PATIENTS
========

Generally, the majority of patients with clinically significant blood loss were approximately 1-year older than those without blood loss (mean age, 61 years *vs* 60 years, respectively; Table **[2](#T2){ref-type="table"}**). Overall 932/51,048 (1.83%) patients in the 51 studies described above experienced clinically significant anemia or blood loss (predefined by a *decrease in hemoglobin ≥2 g/dL and/or hematocrit ≥10% from baseline*). The majority of patients in both groups had follow-up for \>6 months, and baseline demographics were similar when patients with clinically significant blood loss were compared with those without (Table **[2](#T2){ref-type="table"}**) such blood loss.

End Points
----------

In general, patients with clinically significant blood loss had a higher incidence of AEs than those who did not (66% and 58%, respectively; Table **[3](#T3){ref-type="table"}**). The majority of the difference between groups could be accounted for by AEs representing GI disorders or their likely sequelae. The specific AEs of this type that were markedly increased (defined as greater than threefold difference) for patients with clinically significant blood loss versus those without it were: gastric ulcer (1.5% *vs* 0.2%, respectively); GI hemorrhage (0.8% *vs* \<0.1%); esophageal ulcer (0.5% *vs* \<0.1%); melena (1.3% *vs* 0.1%); anemia (8.8% *vs* 0.6%); increase in blood creatinine (1.7% *vs* 0.4%); decrease in hemoglobin (8.9% *vs* 0.2%); decrease in hematocrit (10.4% *vs* 0.5%); decrease in red blood cell count (0.8% *vs* \<0.1%); and hematochezia (1.0% *vs* 0.3%).

However, the incidence of the following *non-GI related AEs* was also markedly higher in patients with clinically significant blood loss compared with patients without such blood loss: coronary artery disease (1.2% *vs* 0.3%, respectively), myocardial infarction (0.6% *vs* 0.2%), and pneumonia (1.7% *vs* 0.4%).

Withdrawals due to AEs were more common among patients who had clinically significant blood loss (17%) than among those who did not (10%) have such blood loss.

DISCUSSION
==========

The findings of this retrospective pooled analysis support the hypothesis that a *decrease in hemoglobin ≥2 g/dL and/or hematocrit ≥10% points from baseline*represents a clinically relevant event. As might be expected, hematologic observations of this type may be associated with pathophysiologic processes that result in either overt bleeding (e.g. GI hemorrhage and melena) or lesions that may reasonably be expected to account for bleeding that cannot be observed directly (e.g. gastric and esophageal ulcers). However, pathophysiologic states resulting from such blood loss, for example a reduction in oxygen-carrying capacity or a compromised immune system, may explain the increased incidence of particular non-GI AEs observed in patients with blood loss (e.g. myocardial infarction, coronary artery disease, and pneumonia). As these kinds of events are relatively rare in clinical trial populations, it is not clear whether the inability to detect other non-GI events of related etiology in this current analysis was a result of underpowering due to limited sample size or due to more mechanistic effects.

The goal of this analysis was to better understand the clinical implications of a *decrease in hemoglobin ≥2 g/dL and/or hematocrit ≥10% points from baseline* over time. Both the CONDOR \[[@R8],[@R9]\] and GI-REASONS \[[@R9]\] trials included this measure of clinically significant blood loss as a component of the predefined composite primary GI end point for "Clinically Significant Upper and Lower GI Events." In contrast to the current analysis, the end point, in these two clinical trials, was adjudicated by an independent expert blinded panel to be of confirmed or likely GI source. We now know the majority of the primary end point events in CONDOR were adjudicated as meeting this prespecified definition of clinically significant blood loss rather than the more traditional end point for evaluation of GI effects for NSAIDs---GI perforations, ulcers, or overt bleeds (PUBs), or "ulcer complications" \[[@R8]\]. Thus, the results of this current respective analysis of data from 51 clinical studies may help to establish the clinical importance of blood loss events that are not readily identifiable as PUBs.

The findings of the CONDOR trial \[[@R8]\] and the previous Celecoxib Long-term Arthritis Safety Study (CLASS) \[[@R10]\] suggest clinically significant blood loss, as defined in the current analysis and the CONDOR trial, is a consequence of the effects of NSAIDs on GI physiology. In both CONDOR and CLASS, decreases in hemoglobin ≥2 g/dL occurred similarly over time, despite differences in trial design, and were prevalent in these patients treated with NSAIDs \[[@R11]\]. In another recent study of 892 randomized participants with chronic knee pain, who were treated with either non-prescription doses of ibuprofen and acetaminophen or two different non-prescription dose combinations of ibuprofen/acetaminophen, up to approximately 18% of all participants had decreases of *hemoglobin ≥2 g/dL in the various treatment groups, supporting the clinical relevance of this safety measure* \[[@R12]\]. Of these three trials for which published data are available, CLASS and CONDOR had decreases in hemoglobin ≥2 g/dL prespecified for analysis; in the CONDOR trial (but not the CLASS trial) these decreases were also adjudicated for association with GI sources.

Strand *et al.,* analyzed 14 randomized clinical trials from the celecoxib database, including more than 14,000 arthritis patients, and discovered treatment in patients with decreases in hemoglobin ≥2 g/dL was associated with no improvement in physical function, contrasting to those patients with no decreases in hemoglobin. Following treatment, the latter group of patients demonstrated improvements in physical functioning, as assessed by the Medical Outcomes Study Short Form with 36 questions (SF-36) \[[@R13]\].

STRENGTHS/LIMITATIONS
=====================

One of the strengths of this analysis was the inclusion of more than 51,000 patients with active disease---OA, RA, or AS---giving a robust sample size. A second strength, was the use of the prespecified definition of clinically significant anemia or blood loss (previously used in both the CONDOR and GI-REASONS randomized clinical trials). However, we should be cautious when interpreting these findings as even in this analysis population of more than 51,000 patients, some of the specific AEs examined occurred in too few patients to provide the most robust information. Furthermore, analysis of trials solely from the celecoxib trial database might exclude relevant trials conducted elsewhere, and while many of the randomized controlled trials included in this pooled analysis had a similar study structure, they were not identical, which could potentially have introduced bias.

CONCLUSION
==========

Clinically significant anemia or blood loss, defined as *decreases in hemoglobin ≥2 g/dL and/or hematocrit by ≥10% from baseline*, may have clinically important adverse consequences beyond the sequelae previously known to be associated with NSAID-related GI effects. The discovery of gastric and esophageal ulcers in the group of patients with a markedly higher incidence of clinically significant blood loss suggests possible occult GI bleeding from this source. The markedly increased incidence for some *non-GI related AE* terms suggests clinically significant blood loss may be especially important in those patients needing all of their oxygen-carrying capacity. Further studies are required to better understand the clinical importance of clinically significant anemia or blood loss.
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###### 

Clinical Studies Included in the Pooled Analysis

                                                   Duration of Treatment                   Treatment Groups
  ------------------------------------------------ --------------------------------------- ------------------------------------------------------------------------------------------------
  **Osteoarthritis and/or Rheumatoid Arthritis**                                           
  N49-96-02-012                                    4 Wks                                   placebo, celecoxib 40 mg BID, celecoxib 200 mg BID, celecoxib 400 mg BID
  N49-96-02-020                                    12 Wks                                  placebo, celecoxib 50 mg BID, celecoxib 100 mg BID, celecoxib 200 mg BID, naproxen 500 mg BID
  N49-96-02-021                                    12 Wks                                  placebo, celecoxib 50 mg BID, celecoxib 100 mg BID, celecoxib 200 mg BID, naproxen 500 mg BID
  N49-96-02-022                                    12 Wks                                  placebo, celecoxib 100 mg BID, celecoxib 200 mg BID, celecoxib 400 mg BID, naproxen 500 mg BID
  N49-96-02-023                                    12 Wks                                  placebo, celecoxib 100 mg BID, celecoxib 200 mg BID, celecoxib 400 mg BID, naproxen 500 mg BID
  I49-96-02-041                                    24 Wks                                  celecoxib 200 mg BID, diclofenac SR 75 mg BID
  I49-96-02-042                                    6 Wks                                   celecoxib 100 mg BID, diclofenac 50 mg BID
  N49-96-02-047                                    4 Wks                                   placebo, celecoxib 25 mg BID, celecoxib 100 mg BID, celecoxib 400 mg BID
  N49-96-02-054                                    12 Wks                                  placebo, celecoxib 50 mg BID, celecoxib 100 mg BID, celecoxib 200 mg BID, naproxen 500 mg BID
  N49-96-02-060                                    6 Wks                                   placebo, celecoxib 100 mg BID, celecoxib 200 mg QD
  N49-96-02-062                                    12 Wks                                  celecoxib 200 mg, naproxen 500 mg BID
  N49-96-02-071                                    12 Wks                                  celecoxib 200 mg BID, diclofenac 75 mg BID, Ibuprofen 800 mg TID
  N49-96-02-087                                    6 Wks                                   placebo, celecoxib 100 mg BID, celecoxib 200 mg QD
  I49-96-02-096                                    12 Wks                                  celecoxib 100 mg BID, celecoxib 200 mg BID, diclofenac 50 mg BID, naproxen 500 mg BID
  N49-96-02-035/102 (CLASS trial)                  Event-driven: median 6-9 months         celecoxib 400 mg BID, ibuprofen 800 mg TID, diclofenac 75 BID
  I49-96-02-105                                    12 Wks                                  celecoxib 100 mg BID, diclofenac 50 mg BID
  I49-96-02-106                                    12 Wks                                  celecoxib 100 mg BID, diclofenac 50 mg BID
  I49-96-02-107                                    12 Wks                                  celecoxib 100 mg BID, diclofenac 50 mg BID
  N49-96-02-118                                    6 Wks                                   placebo, celecoxib 100 mg BID, diclofenac 50 mg TID
  N49-96-02-149                                    6 Wks                                   celecoxib 200 mg QD, rofecoxib 25 mg QD
  N49-96-02-152                                    6 Wks                                   celecoxib 200 mg QD, rofecoxib 25 mg QD
  N49-96-02-181                                    6 Wks                                   celecoxib 200 mg QD, rofecoxib 25 mg QD
  J49-01-02-216                                    4 Wks                                   placebo, celecoxib 100 mg BID, loxoprofen 60 mg TID
  635-IFL-0508-002                                 12 Wks                                  celecoxib 200 mg QD, rofecoxib 25 mg QD, naproxen 500 mg BID
  635-IFL-0508-003                                 6 Wks                                   placebo, celecoxib 200 mg QD, rofecoxib 25 mg QD
  A3191006                                         52 Wks                                  celecoxib 200 mg QD, diclofenac 50 mg BID
  A3191025                                         1 yr[a](#T1F2){ref-type="table-fn"}     celecoxib 200 mg QD, diclofenac 50 mg BID
  A3191051                                         6 Wks                                   placebo, celecoxib 200 mg QD, naproxen 500 mg BID
  A3191052                                         6 Wks                                   placebo, celecoxib 200 mg QD, naproxen 500 mg BID
  A3191053                                         6 Wks                                   placebo, celecoxib 200 mg QD, naproxen 500 mg BID
  A3191062                                         6 Wks                                   placebo, celecoxib 200 mg QD, ibuprofen 800 mg TID
  A3191063                                         6 Wks                                   placebo, celecoxib 200 mg QD, ibuprofen 800 mg TID
  A3191069                                         6 Wks                                   placebo, celecoxib 200 mg QD
  A3191082                                         6 Wks                                   placebo, celecoxib 200 mg QD
  A3191152                                         6 Mths                                  celecoxib 200 mg QD, naproxen 500 mg BID
  COXA-0508-261                                    12 Wks                                  celecoxib 200 mg QD, diclofenac 50 mg TID
  **Ankylosing Spondylitis**                                                               
  F49-98-02-137                                    6 Wks                                   placebo, celecoxib 100 mg BID, ketoprofen 100 mg BID
  N49-01-02-193                                    12 Wks                                  placebo, celecoxib 200 mg QD, celecoxib 400 mg QD, naproxen 500 mg BID
  COXA-0503-243                                    12 Wks                                  celecoxib 200 mg QD, celecoxib 200 mg BID, diclofenac 75 mg SR BID
  COXA-0503-247                                    12 Wks                                  celecoxib 200 mg QD, celecoxib 400 mg QD, diclofenac 75 mg TID
  **Chronic Low Back Pain**                                                                
  J49-01-02-217                                    4 Wks                                   celecoxib 100 mg BID, loxoprofen 60 mg TID
  COXA-0508-244                                    12 Wks                                  placebo, celecoxib 200 mg QD
  COXA-0508-245                                    12 Wks                                  placebo, celecoxib 200 mg QD
  COXA-0508-269                                    12 Wks                                  placebo, celecoxib 200 mg QD, celecoxib 200 mg BID
  A3191174                                         4 Wks                                   celecoxib 200 mg BID, loxoprofen 60 mg TID
  **Alzheimer Disease**                                                                    
  IQ5-97-02-001                                    52 Wks                                  placebo, celecoxib 200 mg BID
  EQ5-98-02-002                                    3 yr[a](#T1F2){ref-type="table-fn"}     placebo, celecoxib 200 mg BID
  NQ5-98-02-005                                    4 Wks                                   placebo, celecoxib 200 mg BID
  **Spontaneous Colorectal Adenomatous Polyps**                                            
  NQ4-00-02-011                                    12 Wks[a](#T1F2){ref-type="table-fn"}   placebo, celecoxib 100 mg BID, celecoxib 200 mg BID, celecoxib 400 mg BID
  EQ4-00-02-018                                    3 y[a](#T1F2){ref-type="table-fn"}      placebo, celecoxib 400 mg QD
  IQ4-99-02-005                                    3y[a](#T1F2){ref-type="table-fn"}       placebo, celecoxib 200 mg BID, celecoxib 400 mg BID

For this analysis, blood loss was predefined as a decrease in hemoglobin ≥2 g/dL and/or hematocrit ≥10% from baseline.

QD: once daily; BID: twice daily; TID: three times daily.

Treatment with study medication was suspended or terminated early.

###### 

Baseline Demographics and Characteristics of Patients Included in the Pooled Analysis

                    Patients with Blood Loss (n=932)   Patients without Blood Loss (n=50,116)
  ----------------- ---------------------------------- ----------------------------------------
  **Age, y**                                           
  Mean              61                                 60
  Median            61                                 61
  Range             21-91                              17-96
  **Race, n (%)**                                      
  White             746 (80)                           38,166 (76)
  Black             54 (5.8)                           3218 (6.4)
  Asian             102 (11)                           5518 (11)
  Other             29 (3)                             2970 (66)
  Missing           1 (0.1)                            244 (0.5)
  **Sex, n (%)**                                       
  Female            547 (59)                           32,861 (66)
  Male              385 (41)                           17,255 (34)
  **Weight, kg**                                       
  Female, n (%)     544 (58)                           32,778 (65)
  Mean              72                                 76
  Median            69                                 73
  Range             36-163                             32-250
  **Weight, kg**                                       
  Male, n (%)       383 (41)                           17,225 (34)
  Mean              87                                 88
  Median            86                                 85
  Range             48-158                             35-232

###### 

Adverse Events (AEs) in Patients with Clinically Significant Anemia/Blood Loss[a](#T3F1){ref-type="table-fn"} Versus those Without (Threshold ≥0.5%)

  ------------------------------------------- ---------------------------------- ----------------------------------------
  AEs, n (%)[b](#T3F2){ref-type="table-fn"}   Patients with Blood Loss (n=932)   Patients without Blood Loss (n=50,116)
  **Any AE**                                  612 (66)                           29,222 (58)
  **GI-Related AEs**                                                             
  Gastric ulcer                               14 (1.5)                           101 (0.2)
  GI hemorrhage                               7 (0.8)                            33 (\< 0.1)
  Esophageal ulcer                            5 (0.5)                            24 (\< 0.1)
  Melena                                      12 (1.3)                           57 (0.1)
  **Potential GI-Related AEs**                                                   
  Anemia                                      82 (8.8)                           317 (0.6)
  Increase in blood creatinine                16 (1.7)                           207 (0.4)
  Decrease in hemoglobin                      83 (8.9)                           120 (0.2)
  Decrease in hematocrit                      97 (10.4)                          228 (0.5)
  Decrease in red blood cell count            7 (0.8)                            23 (\< 0.1)
  Hematochezia                                9 (1.0)                            126 (0.3)
  **Non-GI-Related AEs**                                                         
  Coronary artery disease                     11 (1.2)                           144 (0.3)
  Myocardial infarction                       6 (0.6)                            99 (0.2)
  Pneumonia                                   16 (1.7)                           202 (0.4)
  ------------------------------------------- ---------------------------------- ----------------------------------------

Markedly higher, i.e. threefold difference between treatment groups in the incidence of AEs.

Preferred terms based on MedDRA 11.0.
